1
|
Guo J, Lu Y, Zhang Y, Mugabe S, Wei Z, Borisov OV. Development and fit-for-purpose verification of an LC-MS method for quantitation of hemagglutinin and neuraminidase proteins in influenza virus-like particle vaccine candidates. Anal Biochem 2020; 592:113577. [PMID: 31926146 DOI: 10.1016/j.ab.2020.113577] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Revised: 01/03/2020] [Accepted: 01/04/2020] [Indexed: 12/11/2022]
Abstract
Recombinant influenza Virus-Like Particle (VLP) vaccines are promising vaccine candidates to prevent influenza, contain two major viral antigenic glycoproteins, Hemagglutinin (HA) and Neuraminidase (NA), on the surface of recombinant VLPs. Accurate quantitation of the mass of these antigenic proteins is important to ensure the product quality and proper dosing. Currently, Single Radial Immunodiffusion (SRID) is a recognized assay for determination of the HA immuno-reactive concentration (potency) in vaccine products, based on immuno-reactivity of HA with strain-specific antisera. The SRID assay, however, requires availability of strain-specific and properly calibrated reagents, which can be time-consuming to generate and calibrate. In addition, the assay is not suitable for quantitation of low abundant proteins, such as NA. In order to accelerate the overall production cycle, we have developed and optimized a high-resolution (HR) LC-MS method for absolute quantitation of both HA and NA protein concentrations in influenza VLP vaccine candidates. In this work, we present the method development, optimization and verification of its suitability for the intended purpose, as a prerequisite for its potential application in Quality Control, by assessing specificity, precision and accuracy, detection characteristics, and dynamic linear range. The method can be also used for other HA/NA containing preparations including in-process samples, purified proteins, whole virus preparations, nano-particle and egg-based vaccine preparations, or for calibration of SRID reference antigens.
Collapse
Affiliation(s)
- Jingzhong Guo
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD, 20878, USA
| | - Yali Lu
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD, 20878, USA
| | - Yun Zhang
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD, 20878, USA
| | - Sheila Mugabe
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD, 20878, USA
| | - Ziping Wei
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD, 20878, USA
| | - Oleg V Borisov
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD, 20878, USA.
| |
Collapse
|
2
|
Golchin M, Moghadaszadeh M, Tavakkoli H, Ghanbarpour R, Dastmalchi S. Recombinant M2e-HA2 fusion protein induced immunity responses against intranasally administered H9N2 influenza virus. Microb Pathog 2017; 115:183-188. [PMID: 29273512 DOI: 10.1016/j.micpath.2017.12.050] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2017] [Revised: 12/16/2017] [Accepted: 12/18/2017] [Indexed: 11/17/2022]
Abstract
Influenza is a highly contagious respiratory tract disease and is considered a serious community health problem. Influenza viruses possess multiple conserved epitopes which are used for designing universal vaccines. To this aim, the gene coding for N-terminal part of M2e (SLLTEVET) and HA2 (GLFGAIAGF), was synthesized, linked by a (Gly4Ser)4 peptide linker, and cloned into pGS-21a vector. Afterwards, the construct was transferred into E. coli BL21 (DE3) cells to produce the designed antigenic protein called M2e-HA2. Immunization of mice with these peptides significantly induced humoral immune responses against the influenza virus. Three weeks after the last booster, mice were inoculated intranasally with 1 × 106 EID50 of H9N2 virus. The results indicated that the recombinant M2e-HA2 fusion protein could protect mice against H9N2 virus.
Collapse
Affiliation(s)
- Mehdi Golchin
- Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran
| | - Masoud Moghadaszadeh
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Young Researchers Society, Shahid Bahonar University of Kerman, Kerman, Iran.
| | - Hadi Tavakkoli
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran
| | - Reza Ghanbarpour
- Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran
| | - Siavoush Dastmalchi
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
3
|
Venereo-Sanchez A, Gilbert R, Simoneau M, Caron A, Chahal P, Chen W, Ansorge S, Li X, Henry O, Kamen A. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate. Vaccine 2016; 34:3371-80. [PMID: 27155499 DOI: 10.1016/j.vaccine.2016.04.089] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Revised: 04/21/2016] [Accepted: 04/26/2016] [Indexed: 12/30/2022]
Abstract
Virus-like particles (VLPs) constitute a promising alternative as influenza vaccine. They are non-replicative particles that mimic the morphology of native viruses which make them more immunogenic than classical subunit vaccines. In this study, we propose HEK-293 cells in suspension culture in serum-free medium as an efficient platform to produce large quantities of VLPs. For this purpose, a stable cell line expressing the main influenza viral antigens hemagglutinin (HA) and neuraminidase (NA) (subtype H1N1) under the regulation of a cumate inducible promoter was developed (293HA-NA cells). The production of VLPs was evaluated by transient transfection of plasmids encoding human immunodeficiency virus (HIV) Gag or M1 influenza matrix protein. To facilitate the monitoring of VLPs production, Gag was fused to the green fluorescence protein (GFP). The transient transfection of the gag containing plasmid in 293HA-NA cells increased the release of HA and NA seven times more than its counterpart transfected with the M1 encoding plasmid. Consequently, the production of HA-NA containing VLPs using Gag as scaffold was evaluated in a 3-L controlled stirred tank bioreactor. The VLPs secreted in the culture medium were recovered by ultracentrifugation on a sucrose cushion and ultrafiltered by tangential flow filtration. Transmission electron micrographs of final sample revealed the presence of particles with the average typical size (150-200nm) and morphology of HIV-1 immature particles. The concentration of the influenza glycoproteins on the Gag-VLPs was estimated by single radial immunodiffusion and hemagglutination assay for HA and by Dot-Blot for HA and NA. More significantly, intranasal immunization of mice with influenza Gag-VLPs induced strong antigen-specific mucosal and systemic antibody responses and provided full protection against a lethal intranasal challenge with the homologous virus strain. These data suggest that, with further optimization and characterization the process could support mass production of safer and better-controlled VLPs-based influenza vaccine candidate.
Collapse
Affiliation(s)
- Alina Venereo-Sanchez
- Department of Chemical Engineering, Ecole Polytechnique de Montréal, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council Canada, Montréal, Québec, Canada
| | - Renald Gilbert
- Vaccine Program, Human Health Therapeutics, National Research Council Canada, Montréal, Québec, Canada
| | - Melanie Simoneau
- Vaccine Program, Human Health Therapeutics, National Research Council Canada, Montréal, Québec, Canada
| | - Antoine Caron
- Vaccine Program, Human Health Therapeutics, National Research Council Canada, Montréal, Québec, Canada
| | - Parminder Chahal
- Vaccine Program, Human Health Therapeutics, National Research Council Canada, Montréal, Québec, Canada
| | - Wangxue Chen
- Human Health Therapeutics, National Research Council Canada, Ottawa, Ontario, Canada
| | - Sven Ansorge
- Vaccine Program, Human Health Therapeutics, National Research Council Canada, Montréal, Québec, Canada
| | - Xuguang Li
- Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada, Ottawa, Ontario, Canada
| | - Olivier Henry
- Department of Chemical Engineering, Ecole Polytechnique de Montréal, Montréal, Québec, Canada
| | - Amine Kamen
- Department of Bioengineering, McGill University, Montréal, Québec, Canada.
| |
Collapse
|
4
|
Domínguez A, Godoy P, Torner N. The Effectiveness of Influenza Vaccination in Different Groups. Expert Rev Vaccines 2016; 15:751-64. [PMID: 26775669 DOI: 10.1586/14760584.2016.1142878] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Annual administration of the seasonal influenza vaccine, especially to persons known to be at elevated risk for developing serious complications, is the focus of current efforts to reduce the impact of influenza. The main factors influencing estimated inactivated influenza vaccine efficacy and effectiveness, the results obtained in different population groups, current vaccination strategies and the possible advantages of new vaccines are discussed. The available evidence suggests that influenza vaccines are less effective in the elderly than in young adults, but vaccination is encouraged by public health institutions due to higher mortality and complications. There is no consensus on universal vaccination of children yet economic studies suggest that yearly paediatric vaccination is cost saving. The benefits of herd immunity generated by paediatric vaccination require further study. Newer vaccines should be more and more-broadly protective, stable, easy to manufacture and administer and highly immunogenic across all population groups.
Collapse
Affiliation(s)
- Angela Domínguez
- a Department de Salut Pública , Universitat de Barcelona , Barcelona , Spain.,b CIBER Epidemiologia y Salut Pública (CIBERESP) , Madrid , Spain
| | - Pere Godoy
- b CIBER Epidemiologia y Salut Pública (CIBERESP) , Madrid , Spain.,c Agencia de Salut Pública de Catalunya , Generalitat de Catalunya , Barcelona , Spain
| | - Nuria Torner
- a Department de Salut Pública , Universitat de Barcelona , Barcelona , Spain.,b CIBER Epidemiologia y Salut Pública (CIBERESP) , Madrid , Spain.,c Agencia de Salut Pública de Catalunya , Generalitat de Catalunya , Barcelona , Spain
| |
Collapse
|
5
|
Dhanwani R, Zhou Y, Huang Q, Verma V, Dileepan M, Ly H, Liang Y. A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose. J Virol 2015; 90:2551-60. [PMID: 26676795 PMCID: PMC4810697 DOI: 10.1128/jvi.02705-15] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Accepted: 12/11/2015] [Indexed: 01/24/2023] Open
Abstract
UNLABELLED Pichinde virus (PICV) is a bisegmented enveloped RNA virus that targets macrophages and dendritic cells (DCs) early in infection and induces strong innate and adaptive immunity in mice. We have developed a reverse genetics system to produce live recombinant PICV (strain P18) with a trisegmented RNA genome (rP18tri), which encodes all four PICV gene products and as many as two foreign genes. We have engineered the vector to express the green fluorescent protein (GFP) reporter gene (abbreviated as G in virus designations) and either the hemagglutination (HA [H]) or the nucleoprotein (NP [P]) gene of the influenza A/PR8 virus. The trisegmented viruses rP18tri-G/H and rP18tri-G/P showed slightly reduced growth in vitro and expressed HA and NP, respectively. Mice immunized with rP18tri-G/H were completely protected against lethal influenza virus challenge even 120 days after immunization. These rP18tri-based vectors could efficiently induce both neutralizing antibodies and antigen-specific T cell responses via different immunization routes. Interestingly, the immune responses were significantly increased upon a booster dose and remained at high levels even after three booster doses. In summary, we have developed a novel PICV-based live vaccine vector that can express foreign antigens to induce strong humoral and cell-mediated immunity and is ideal for a prime-and-boost vaccination strategy. IMPORTANCE We have developed a novel Pichinde virus (PICV)-based live viral vector, rP18tri, that packages three RNA segments and encodes as many as two foreign genes. Using the influenza virus HA and NP genes as model antigens, we show that this rP18tri vector can induce strong humoral and cellular immunity via different immunization routes and can lead to protection in mice. Interestingly, a booster dose further enhances the immune responses, a feature that distinguishes this from other known live viral vectors. In summary, our study demonstrates a unique feature of this live rP18tri vector to be used as a novel vaccine platform for a prime-and-boost vaccination strategy.
Collapse
MESH Headings
- Animals
- Antibodies, Neutralizing/blood
- Antibodies, Viral/blood
- Disease Models, Animal
- Drug Carriers
- Female
- Gene Expression
- Genes, Reporter
- Genetic Vectors
- Green Fluorescent Proteins/analysis
- Green Fluorescent Proteins/genetics
- Guinea Pigs
- Hemagglutinin Glycoproteins, Influenza Virus/genetics
- Hemagglutinin Glycoproteins, Influenza Virus/immunology
- Influenza Vaccines/administration & dosage
- Influenza Vaccines/genetics
- Influenza Vaccines/immunology
- Male
- Mice, Inbred C57BL
- Nucleocapsid Proteins
- Orthomyxoviridae Infections/prevention & control
- Pichinde virus/genetics
- RNA-Binding Proteins/genetics
- RNA-Binding Proteins/immunology
- Recombinant Proteins/genetics
- Recombinant Proteins/immunology
- Survival Analysis
- T-Lymphocytes/immunology
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
- Viral Core Proteins/genetics
- Viral Core Proteins/immunology
Collapse
Affiliation(s)
- Rekha Dhanwani
- Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, Minnesota, USA
| | - Yanqin Zhou
- Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, Minnesota, USA College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, China
| | - Qinfeng Huang
- Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, Minnesota, USA Department of Swine Infectious Diseases, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China
| | - Vikram Verma
- Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, Minnesota, USA
| | - Mythili Dileepan
- Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, Minnesota, USA
| | - Hinh Ly
- Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, Minnesota, USA
| | - Yuying Liang
- Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, Minnesota, USA
| |
Collapse
|
6
|
Bicho D, Santos B, Caramelo-Nunes C, Sousa A, Sousa F, Queiroz J, Tomaz C. Application of ethylenediamine monolith to purify a hemagglutinin influenza deoxyribonucleic acid-based vaccine. Sep Purif Technol 2015. [DOI: 10.1016/j.seppur.2015.09.046] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
7
|
Technology Resource, Distribution, and Development Characteristics of Global Influenza Virus Vaccine: A Patent Bibliometric Analysis. PLoS One 2015; 10:e0136953. [PMID: 26372160 PMCID: PMC4570820 DOI: 10.1371/journal.pone.0136953] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Accepted: 08/10/2015] [Indexed: 11/19/2022] Open
Abstract
Influenza virus vaccine (IVV) is a promising research domain that is closely related to global health matters, which has been acknowledged not only by scientists and technology developers, but also by policy-makers. Meanwhile, patents encompass valuable technological information and reflect the latest technological inventions as well as the innovative capability of a nation. However, little research has examined this up-and-coming research field using patent bibliometric method. Thus, this paper (a) designs the technology classification system and search strategy for the identification of IVV; and (b) presents a longitudinal analysis of the global IVV development based on the European Patent Office (EPO) patents. Bibliometric analysis is used to rank countries, institutions, inventors and technology subfields contributing to IVV technical progress. The results show that the global trends of IVV are a multi-developing feature of variety but an uneven technical resource distribution. Although the synthetic peptide vaccine is a comparatively young field, it already demonstrates the powerful vitality and the enormous development space. With the worldwide competition increasing, all nations especially China should be looking to increase devotion, enhance capability and regard effectiveness of technological innovation.
Collapse
|
8
|
Bitrus Y, Andrew JN, Owolodun OA, Luka PD, Umaru DA. The reoccurrence of H5N1 outbreaks necessitates the development of safe and effective influenza vaccine technologies for the prevention and control of avian influenza in Sub-Saharan Africa. ACTA ACUST UNITED AC 2015. [DOI: 10.5897/bmbr2015.0246] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
9
|
Wu C, Chen W, Chen J, Han B, Peng Z, Ge F, Wei B, Liu M, Zhang M, Qian C, Hou Z, Liu G, Guo C, Wang Y, Kitazato K, Yu G, Zou C, Xiong S. Preparation of monoPEGylated Cyanovirin-N's derivative and its anti-influenza A virus bioactivity in vitro and in vivo. J Biochem 2015; 157:539-48. [PMID: 25713409 PMCID: PMC8356848 DOI: 10.1093/jb/mvv013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Accepted: 12/31/2014] [Indexed: 11/12/2022] Open
Abstract
Influenza A virus (IAV) has been raising public health and safety concerns worldwide. Cyanovirin-N (CVN) is a prominent anti-IAV candidate, but both cytotoxicity and immunogenicity have hindered the development of this protein as a viable therapy. In this article, linker-CVN (LCVN) with a flexible and hydrophilic polypeptide at the N-terminus was efficiently produced from the cytoplasm of Escherichia coli at a >15-l scale. PEGylation at the N-terminal α-amine of LCVN was also reformed as 20 kDa PEGylated linkered Cyanovirin-N (PEG20k-LCVN). The 50% effective concentrations of PEG20k-LCVN were 0.43 ± 0.11 µM for influenza A/HK/8/68 (H3N2) and 0.04 ± 0.02 µM for A/Swan/Hokkaido/51/96 (H5N3), dramatically lower than that of the positive control, Ribavirin (2.88 ± 0.66 × 10(3) µM and 1.79 ± 0.62 × 10(3) µM, respectively). A total of 12.5 µM PEG20k-LCVN effectively inactivate the propagation of H3N2 in chicken embryos. About 2.0 mg/kg/day PEG20k-LCVN increased double the survival rate (66.67%, P = 0.0378) of H3N2 infected mice, prolonged the median survival period, downregulated the mRNA level of viral nuclear protein and decreased (attenuated) the pathology lesion in mice lung. A novel PEGylated CVN derivative, PEG20k-LCVN, exhibited potent and strain-dependent anti-IAV activity in nanomolar concentrations in vitro, as well as in micromolar concentration in vivo.
Collapse
Affiliation(s)
- Chongchao Wu
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Wei Chen
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Jia Chen
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Bo Han
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Zhou Peng
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Feng Ge
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Bo Wei
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Mingxian Liu
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Meiying Zhang
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Chuiwen Qian
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Zhibo Hou
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Ge Liu
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Chaowan Guo
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Yifei Wang
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Kaio Kitazato
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Guoying Yu
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Chunbin Zou
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Sheng Xiong
- Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, Department of Cellular Biology, Jinan University, Guangzhou 510632, Guangdong, People's Republic of China; Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Centre for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China; Department of Pharmacy, College of Food and Pharmacy & Medical, Zhejiang Ocean University, Zhoushan 316002, People's Republic of China; Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, People's Republic of China; Division of Molecular Pharmacology of Infectious Agents, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Nagasaki Prefecture 852-8521, Japan; and Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
| |
Collapse
|
10
|
Greer AL. Early vaccine availability represents an important public health advance for the control of pandemic influenza. BMC Res Notes 2015; 8:191. [PMID: 25953076 PMCID: PMC4427977 DOI: 10.1186/s13104-015-1157-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Accepted: 04/30/2015] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Traditional processes for the production of pandemic influenza vaccines are not capable of producing a vaccine that could be deployed sooner than 5-6 months after strain identification. Plant-based vaccine technologies are of public health interest because they represent an opportunity to begin vaccinating earlier. METHODS We used an age- and risk- structured disease transmission model for Canada to evaluate the potential impact of a plant-produced vaccine available for rapid deployment (within 1-3 months) compared to an egg-based vaccine timeline. RESULTS We found that in the case of a mildly transmissible virus (R0 = 1.3), depending on the amount of plant-based vaccine produced per week, severe clinical outcomes could be decreased by 60-100 % if vaccine was available within 3 months of strain identification. However, in the case of a highly transmissible virus (R0 = 2.0), a delay of 3 months does not change clinical outcomes regardless of the level of weekly vaccine availability. If transmissibility is high, the only strategy that can impact clinical outcomes occurs if vaccine production is high and available within 2 months. CONCLUSIONS Pandemic influenza vaccines produced by plants, change the timeline of pandemic vaccine availability in a way that could significantly mitigate the impact of the next influenza pandemic.
Collapse
Affiliation(s)
- Amy L Greer
- Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, ON, N1G 2W1, Canada.
| |
Collapse
|
11
|
Current and emerging cell culture manufacturing technologies for influenza vaccines. BIOMED RESEARCH INTERNATIONAL 2015; 2015:504831. [PMID: 25815321 PMCID: PMC4359798 DOI: 10.1155/2015/504831] [Citation(s) in RCA: 95] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 02/05/2015] [Accepted: 02/16/2015] [Indexed: 01/08/2023]
Abstract
Annually, influenza virus infects millions of people worldwide. Vaccination programs against seasonal influenza infections require the production of hundreds of million doses within a very short period of time. The influenza vaccine is currently produced using a technology developed in the 1940s that relies on replicating the virus in embryonated hens' eggs. The monovalent viral preparation is inactivated and purified before being formulated in trivalent or tetravalent influenza vaccines. The production process has depended on a continuous supply of eggs. In the case of pandemic outbreaks, this mode of production might be problematic because of a possible drastic reduction in the egg supply and the low flexibility of the manufacturing process resulting in a lack of supply of the required vaccine doses in a timely fashion. Novel production systems using mammalian or insect cell cultures have emerged to overcome the limitations of the egg-based production system. These industrially well-established production systems have been primarily selected for a faster and more flexible response to pandemic threats. Here, we review the most important cell culture manufacturing processes that have been developed in recent years for mass production of influenza vaccines.
Collapse
|
12
|
Jacquet N, Navarre C, Desmecht D, Boutry M. Hydrophobin fusion of an influenza virus hemagglutinin allows high transient expression in Nicotiana benthamiana, easy purification and immune response with neutralizing activity. PLoS One 2014; 9:e115944. [PMID: 25541987 PMCID: PMC4277400 DOI: 10.1371/journal.pone.0115944] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2014] [Accepted: 11/30/2014] [Indexed: 12/02/2022] Open
Abstract
The expression of recombinant hemagglutinin in plants is a promising alternative to the current egg-based production system for the influenza vaccines. Protein-stabilizing fusion partners have been developed to overcome the low production yields and the high downstream process costs associated with the plant expression system. In this context, we tested the fusion of hydrophobin I to the hemagglutinin ectodomain of the influenza A (H1N1)pdm09 virus controlled by the hybrid En2PMA4 transcriptional promoter to rapidly produce high levels of recombinant antigen by transient expression in agro-infiltrated Nicotiana benthamiana leaves. The fusion increased the expression level by a factor of ∼ 2.5 compared to the unfused protein allowing a high accumulation level of 8.6% of the total soluble proteins. Hemagglutinin was located in ER-derived protein bodies and was successfully purified by combining an aqueous-two phase partition system and a salting out step. Hydrophobin interactions allowed the formation of high molecular weight hemagglutinin structures, while unfused proteins were produced as monomers. Purified protein was shown to be biologically active and to induce neutralizing antibodies after mice immunization. Hydrophobin fusion to influenza hemagglutinin might therefore be a promising approach for rapid, easy, and low cost production of seasonal or pandemic influenza vaccines in plants.
Collapse
Affiliation(s)
- Nicolas Jacquet
- Institute of Life Sciences, University of Louvain, Louvain-la-Neuve, Belgium
| | - Catherine Navarre
- Institute of Life Sciences, University of Louvain, Louvain-la-Neuve, Belgium
| | - Daniel Desmecht
- Department of Pathology, Faculty of Veterinary Medicine, University of Liège, Liège, Belgium
| | - Marc Boutry
- Institute of Life Sciences, University of Louvain, Louvain-la-Neuve, Belgium
| |
Collapse
|
13
|
Abstract
The currently available influenza vaccines were developed in the 1930s through the 1960s using technologies that were state-of-the art for the times. Decades of advancement in virology and immunology have provided the tools for making better vaccines against influenza virus. Among young children, live attenuated vaccine had significantly better efficacy than inactivated vaccine. An evaluation of the risks and benefits indicates that live attenuated vaccine should be a highly effective, safe vaccine for children 12 to 59 months of age who do not have a history of asthma or wheezing. Otherwise, MF59 adjuvanted influenza vaccine, ATIV was well tolerated in healthy young children and elderly after each of 3 doses and induced greater, longer-lasting, and broader immune responses than a nonadjuvanted trivalent inactivated influenza vaccine, TIV. The enhanced immunogenicity of the adjuvanted vaccine was most evident in very young children and for the B vaccine strain. In case of AS03 ATIV, the safety signal of increased narcolepsy diagnoses following the start of the pandemic vaccination campaign as observed in Sweden and Finland could be observed with this approach. An increase in narcolepsy diagnoses was not observed in other countries, where vaccination coverage was low in the affected age group, or did not follow influenza. A(H1N1)pdm09 vaccination. Patient level analyses in these countries are being conducted to verify the signal in more detail. In conclusion, current improved influenza vaccines are; in the problem target groups are children aged 6-24 months and people over 65 years old of age. Only ATIV has shown significantly greater efficacy than TIV, and its safe.
Collapse
Affiliation(s)
- Osamu Kobayashi
- Faculty of Health Science, Kyorin University , 6-20-2, Shinkawa, Mitaka, Tokyo 181-8611, Japan ; Kyorin University Hospital , 6-20-2, Shinkawa, Mitaka, Tokyo 181-8611, Japan
| |
Collapse
|
14
|
Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, Rosales-Mendoza S. An overview of bioinformatics tools for epitope prediction: implications on vaccine development. J Biomed Inform 2014; 53:405-14. [PMID: 25464113 DOI: 10.1016/j.jbi.2014.11.003] [Citation(s) in RCA: 254] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2014] [Revised: 09/16/2014] [Accepted: 11/03/2014] [Indexed: 10/24/2022]
Abstract
Exploitation of recombinant DNA and sequencing technologies has led to a new concept in vaccination in which isolated epitopes, capable of stimulating a specific immune response, have been identified and used to achieve advanced vaccine formulations; replacing those constituted by whole pathogen-formulations. In this context, bioinformatics approaches play a critical role on analyzing multiple genomes to select the protective epitopes in silico. It is conceived that cocktails of defined epitopes or chimeric protein arrangements, including the target epitopes, may provide a rationale design capable to elicit convenient humoral or cellular immune responses. This review presents a comprehensive compilation of the most advantageous online immunological software and searchable, in order to facilitate the design and development of vaccines. An outlook on how these tools are supporting vaccine development is presented. HIV and influenza have been taken as examples of promising developments on vaccination against hypervariable viruses. Perspectives in this field are also envisioned.
Collapse
Affiliation(s)
- Ruth E Soria-Guerra
- Laboratorio de Ingeniería de Biorreactores, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP 78210, Mexico
| | - Ricardo Nieto-Gomez
- Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP 78210, Mexico
| | - Dania O Govea-Alonso
- Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP 78210, Mexico
| | - Sergio Rosales-Mendoza
- Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP 78210, Mexico.
| |
Collapse
|
15
|
Duan Y, Gu H, Chen R, Zhao Z, Zhang L, Xing L, Lai C, Zhang P, Li Z, Zhang K, Wang Z, Zhang S, Wang X, Yang P. Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine. PLoS One 2014; 9:e99322. [PMID: 24937303 PMCID: PMC4061005 DOI: 10.1371/journal.pone.0099322] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2014] [Accepted: 05/13/2014] [Indexed: 12/12/2022] Open
Abstract
In early spring 2013, the emergence of the influenza A (H7N9) virus in humans in Eastern China raised concerns of a new influenza pandemic. Development of a safe and effective H7N9 influenza vaccine is urgently needed. To this end, we first synthesized the hemagglutinin (HA) and neuraminidase (NA) genes of the influenza A (H7N9) virus A/AnHui/1/2013. Using reverse genetics, we rescued a reassortant virus (H7N9/PR8) that contained the HA and NA genes from wild-type H7N9 and six genes encoding internal proteins from the A/Puerto Rico/8/34 (PR8) virus. Next, the pathogenicity of the reassortant virus was evaluated both in vivo and in vitro. We found that the virus was non-pathogenic in mice and was stable after serial passaging in eggs. Furthermore, we found that a monovalent influenza A (H7N9) split vaccine prepared from the virus was immunogenic in mice and ferrets. When given intramuscularly, the vaccine (two doses of at least 15-µg) completely protected mice from normally lethal wild-type H7N9 virus challenge. In summary, our H7N9 vaccine, developed over a short time, is a potential candidate for further clinical evaluation and human use.
Collapse
Affiliation(s)
- Yueqiang Duan
- Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China
| | - Hongjing Gu
- Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China
| | - Rui Chen
- Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China
- Department of Pathogenic Biology and Medical Immunology, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China
| | - Zhongpeng Zhao
- Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China
| | - Liangyan Zhang
- Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China
| | - Li Xing
- Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China
| | - Chengcai Lai
- Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China
| | | | - Zhiwei Li
- 302 Military Hospital, Beijing, China
| | | | | | | | - Xiliang Wang
- Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China
- * E-mail: (XW); (PY)
| | - Penghui Yang
- Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China
- 302 Military Hospital, Beijing, China
- * E-mail: (XW); (PY)
| |
Collapse
|
16
|
Even-Or O, Samira S, Ellis R, Kedar E, Barenholz Y. Adjuvanted influenza vaccines. Expert Rev Vaccines 2014; 12:1095-108. [PMID: 24053401 DOI: 10.1586/14760584.2013.825445] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Influenza is one of the most common causes of human morbidity and mortality that is preventable by vaccination. Immunization with available vaccines provides incomplete protection against illness caused by influenza virus, especially in high-risk groups such as the elderly and young children. Thus, more efficacious vaccines are needed for the entire population, and all the more so for high-risk groups. One way to improve immune responses and protection is to formulate the vaccine with antigen carriers and/or adjuvants, which can play an important role in improving immune responses and delivery to antigen-presenting cells, especially for a vaccine like influenza that is based on protein antigens usually administered without a carrier or adjuvant. In this review, the authors present an overview of available vaccines, focusing on research and development of new adjuvants used in influenza vaccines, as well as adjuvanted influenza vaccines aimed to improve immune responses, protection and breadth of coverage for influenza.
Collapse
Affiliation(s)
- Orli Even-Or
- Laboratory of Membrane and Liposome Research, Department of Biochemistry, The Hebrew University-Hadassah Medical School, P.O. Box 12272, Jerusalem 91120, Israel
| | | | | | | | | |
Collapse
|
17
|
Genzel Y, Rödig J, Rapp E, Reichl U. Vaccine production: upstream processing with adherent or suspension cell lines. Methods Mol Biol 2014; 1104:371-393. [PMID: 24297427 DOI: 10.1007/978-1-62703-733-4_23] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The production of viral vaccines in cell culture can be accomplished with primary, diploid, or continuous (transformed) cell lines. Each cell line, each virus type, and each vaccine preparation require the specific design of upstream and downstream processing. Media have to be selected as well as production vessels, cultivation conditions, and modes of operation. Many viruses only replicate to high titers in adherently growing cells, but similar to processes established for recombinant protein production, an increasing number of suspension cell lines is being evaluated for future use. Here, we describe key issues to be considered for the establishment of large-scale virus production in bioreactors. As an example upstream processing of cell culture-derived influenza virus production is described in more detail for adherently growing and for suspension cells. In particular, use of serum-containing, serum-free, and chemically defined media as well as choice of cultivation vessel are considered.
Collapse
Affiliation(s)
- Yvonne Genzel
- Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany
| | | | | | | |
Collapse
|
18
|
van Els C, Mjaaland S, Næss L, Sarkadi J, Gonczol E, Smith Korsholm K, Hansen J, de Jonge J, Kersten G, Warner J, Semper A, Kruiswijk C, Oftung F. Fast vaccine design and development based on correlates of protection (COPs). Hum Vaccin Immunother 2014; 10:1935-48. [PMID: 25424803 PMCID: PMC4186026 DOI: 10.4161/hv.28639] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 03/14/2014] [Accepted: 03/24/2014] [Indexed: 01/02/2023] Open
Abstract
New and reemerging infectious diseases call for innovative and efficient control strategies of which fast vaccine design and development represent an important element. In emergency situations, when time is limited, identification and use of correlates of protection (COPs) may play a key role as a strategic tool for accelerated vaccine design, testing, and licensure. We propose that general rules for COP-based vaccine design can be extracted from the existing knowledge of protective immune responses against a large spectrum of relevant viral and bacterial pathogens. Herein, we focus on the applicability of this approach by reviewing the established and up-coming COPs for influenza in the context of traditional and a wide array of new vaccine concepts. The lessons learnt from this field may be applied more generally to COP-based accelerated vaccine design for emerging infections.
Collapse
Affiliation(s)
- Cécile van Els
- National Institute for Public Health and the Environment; Bilthoven, the Netherlands
| | | | - Lisbeth Næss
- Norwegian Institute of Public Health; Oslo, Norway
| | - Julia Sarkadi
- National Center for Epidemiology (NCE); Budapest, Hungary
| | - Eva Gonczol
- National Center for Epidemiology (NCE); Budapest, Hungary
| | | | - Jon Hansen
- Statens Serum Institut; Copenhagen, Denmark
| | - Jørgen de Jonge
- National Institute for Public Health and the Environment; Bilthoven, the Netherlands
| | - Gideon Kersten
- Institute for Translational Vaccinology; Bilthoven, the Netherlands
- Leiden Academic Center for Drug Research; University of Leiden; The Netherlands
| | | | | | - Corine Kruiswijk
- Institute for Translational Vaccinology; Bilthoven, the Netherlands
| | | |
Collapse
|
19
|
Abstract
Influenza is a worldwide public health concern. Since the introduction of trivalent influenza vaccine in 1978, vaccination has been the primary means of prevention and control of influenza. Current influenza vaccines have moderate efficacy, good safety, and acceptable tolerability; however, they have unsatisfactory efficacy in older adults, are dependent on egg supply for production, and are time-consuming to manufacture. This review outlines the unmet medical needs of current influenza vaccines. Recent developments in influenza vaccines are also described.
Collapse
Affiliation(s)
- Ji Yun Noh
- Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. ; Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea
| | - Woo Joo Kim
- Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. ; Asian Pacific Influenza Institute, Korea University College of Medicine, Seoul, Korea. ; Transgovernmental Enterprise for Pandemic Influenza in Korea, Seoul, Korea
| |
Collapse
|
20
|
Jang YH, Lee EY, Byun YH, Jung EJ, Lee YJ, Lee YH, Lee KH, Lee J, Seong BL. Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains. Vaccine 2013; 32:535-43. [PMID: 24342248 DOI: 10.1016/j.vaccine.2013.12.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2013] [Revised: 11/19/2013] [Accepted: 12/02/2013] [Indexed: 11/17/2022]
Abstract
Influenza virus continues to take a heavy toll on human health and vaccination remains the mainstay of efforts to reduce the clinical impact imposed by viral infections. Proven successful for establishing live attenuated vaccine donor strains, cold-adapted live attenuated influenza vaccines (CAIVs) have become an attractive modality for controlling the virus infection. Previously, we developed the cold-adapted strains A/X-31 and B/Lee/40 as novel donor strains of CAIVs against influenza A and B viruses. In this study, we investigated the protective immune responses of both mono- and trivalent vaccine formulations in the mouse model. Two type A vaccines and one type B vaccine against A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Shangdong/7/97 in the background of the A/X-31 ca or B/Lee/40 ca were generated by a reassortment procedure and evaluated for their immunogenicity and protective efficacy. Each monovalent vaccine elicited high levels of serum antibodies and conferred complete protection against homologous wild type virus infection. As compared to the monovalent vaccines, trivalent formulation induced higher levels of type A-specific serum antibodies and slightly lower levels of type B-specific antibodies, suggesting an immunological synergism within type A viruses and an interference in the replication of type B virus. Relatively lower type B-specific immunogenicity in trivalent vaccine formulation could be effectively implemented by increasing the vaccine dose of influenza B virus. These results of immunogenicity, protection efficacy, and immunological synergism between type A vaccines provide an experimental basis for optimal composition of trivalent vaccines for subsequent developments of multivalent CAIVs against seasonal and pandemic influenza viruses.
Collapse
Affiliation(s)
- Yo Han Jang
- Laboratory of Molecular Medicine, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea
| | - Eun-Young Lee
- Laboratory of Molecular Medicine, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea
| | - Young Ho Byun
- Laboratory of Molecular Medicine, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea
| | - Eun-Ju Jung
- Laboratory of Molecular Medicine, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea
| | - Yoon Jae Lee
- Laboratory of Molecular Medicine, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea
| | - Yun Ha Lee
- Laboratory of Molecular Medicine, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea
| | - Kwang-Hee Lee
- Laboratory of Molecular Medicine, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea
| | - Jinhee Lee
- Laboratory of Molecular Medicine, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea
| | - Baik Lin Seong
- Laboratory of Molecular Medicine, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea; Translational Vaccine Research Center, Yonsei University, Seoul, South Korea; Translational Research Center for Protein Function Control, Yonsei University, Seoul, South Korea.
| |
Collapse
|
21
|
Skibinski DAG, Hanson BJ, Lin Y, von Messling V, Jegerlehner A, Tee JBS, Chye DH, Wong SKK, Ng AAP, Lee HY, Au B, Lee BTK, Santoso L, Poidinger M, Fairhurst AM, Matter A, Bachmann MF, Saudan P, Connolly JE. Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine. PLoS One 2013; 8:e76571. [PMID: 24204639 PMCID: PMC3799843 DOI: 10.1371/journal.pone.0076571] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2013] [Accepted: 08/25/2013] [Indexed: 01/19/2023] Open
Abstract
Influenza pandemics can spread quickly and cost millions of lives; the 2009 H1N1 pandemic highlighted the shortfall in the current vaccine strategy and the need for an improved global response in terms of shortening the time required to manufacture the vaccine and increasing production capacity. Here we describe the pre-clinical assessment of a novel 2009 H1N1 pandemic influenza vaccine based on the E. coli-produced HA globular head domain covalently linked to virus-like particles derived from the bacteriophage Qβ. When formulated with alum adjuvant and used to immunize mice, dose finding studies found that a 10 µg dose of this vaccine (3.7 µg globular HA content) induced antibody titers comparable to a 1.5 µg dose (0.7 µg globular HA content) of the licensed 2009 H1N1 pandemic vaccine Panvax, and significantly reduced viral titers in the lung following challenge with 2009 H1N1 pandemic influenza A/California/07/2009 virus. While Panvax failed to induce marked T cell responses, the novel vaccine stimulated substantial antigen-specific interferon-γ production in splenocytes from immunized mice, alongside enhanced IgG2a antibody production. In ferrets the vaccine elicited neutralizing antibodies, and following challenge with influenza A/California/07/2009 virus reduced morbidity and lowered viral titers in nasal lavages.
Collapse
Affiliation(s)
- David A. G. Skibinski
- A*STAR Program in Translational Research on Infectious Disease, Agency for Science, Technology and Research, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research, Singapore
| | | | - Yufang Lin
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research, Singapore
| | - Veronika von Messling
- Institut National de la Recherche Scientifique (INRS)- Institut Armand-Frappier, University of Quebec, Quebec, Canada
| | | | | | - De Hoe Chye
- Defence Science Organisation (DSO) National Laboratories, Singapore
| | | | - Amanda A. P. Ng
- A*STAR Program in Translational Research on Infectious Disease, Agency for Science, Technology and Research, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research, Singapore
| | - Hui Yin Lee
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research, Singapore
| | - Bijin Au
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research, Singapore
| | - Bernett T. K. Lee
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research, Singapore
| | - Lucia Santoso
- Experimental Therapeutics Centre (ETC), Agency for Science, Technology and Research, Singapore
| | - Michael Poidinger
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research, Singapore
| | - Anna-Marie Fairhurst
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research, Singapore
| | - Alex Matter
- Experimental Therapeutics Centre (ETC), Agency for Science, Technology and Research, Singapore
| | | | | | - John E. Connolly
- A*STAR Program in Translational Research on Infectious Disease, Agency for Science, Technology and Research, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research, Singapore
| |
Collapse
|
22
|
Girard MP, Tam JS, Pervikov Y, Katz JM. Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013. Vaccine 2013; 31:3766-71. [PMID: 23810374 DOI: 10.1016/j.vaccine.2013.06.047] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Accepted: 06/13/2013] [Indexed: 01/08/2023]
Abstract
On January 24-26, 2013, the World Health Organization convened the first integrated meeting on "The development and clinical trials of vaccines that induce broadly protective and long-lasting immune responses" to review the current status of development and clinical evaluation of novel influenza vaccines as well as strategies to produce and deliver vaccines in novel ways. Special attention was given to the development of possible universal influenza vaccines. Other topics that were addressed included an update on clinical trials of pandemic and seasonal influenza vaccines in high-risk groups and vaccine safety, as well as regulatory issues.
Collapse
Affiliation(s)
- Marc P Girard
- Unversity Paris-Diderot, French National Academy of Medicine, 16 rue Bonaparte, 75006 Paris, France.
| | | | | | | |
Collapse
|